ConductScience.org, home

Paper7844593

Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.

Fields KK and 9 others. J Clin Oncol, 1995. Cited by 76 papers, by iCite.

Cite this record

ConductScience Library. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile. Papers, record 7844593. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/7844593

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
PubMed
Journal
J Clin Oncol
PubMed
Year
1995
PubMed
Publication types
Clinical Trial, Clinical Trial, Phase I, Comparative Study, Journal Article, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
76
iCite
Relative citation ratio, by iCite
2.65
iCite
Revised in PubMed
2017-02-10
PubMed

Authors10

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Fields KKK K
2Elfenbein GJG J
3Lazarus HMH M
4Cooper BWB W
5Perkins JBJ B
6Creger RJR J
7Ballester OFO F
8Hiemenz JHJ H
9Janssen WEW E
10Zorsky PEP E

Source PubMed

Download CSV of authors

Topics24

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Antineoplastic Combined Chemotherapy ProtocolsMajor topic
Hematopoietic Stem Cell TransplantationMajor topic
Acute Disease
Adolescent
Adult
Aged
Breast Neoplasms
Cisplatin
Drug Tolerance
Etoposide
Female
Germinoma
Hodgkin Disease
Humans
Ifosfamide
Leukemia
Lymphoma, Non-Hodgkin
Male
Middle Aged
Ovarian Neoplasms
Prognosis
Sarcoma
Testicular Neoplasms
Transplantation, Autologous

Source PubMed

Download CSV of topics

Grants1

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated by
P30CA43703NCI NIH HHSUnited StatesP30CA043703PubMed and NIH

Source NIH RePORTER

Download CSV of grants

Comments and corrections1

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

KindPMIDTitleIn Papers
Comment in7602373High-dose ifosfamide, carboplatin, and etoposide with autologous stem-cell support.https://conductscience.org/library/papers/7602373

Source PubMed

Download CSV of comments and corrections

Cited by11

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 76 citations.

PMIDTitleJournalYearIn PapersSource
34777885The Use of Etoposide, Ara-Cytarabine, and Melphalan (EAM) Conditioning Chemotherapy in Autologous Stem Cell Transplantation (ASCT) for a Patient with Relapsed Hodgkin's Lymphoma.Case Rep Hematol2021https://conductscience.org/library/papers/34777885PubMed
33707839Conditioning Regimens for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Stem Cell Transplantation: BEAM Versus High Dose ICE.Indian J Hematol Blood Transfus2021https://conductscience.org/library/papers/33707839PubMed
26377357Finding the Optimal Conditioning Regimen for Relapsed/Refractory Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation: A Retrospective Comparison of BEAM and High-Dose ICE.Turk J Haematol2016https://conductscience.org/library/papers/26377357PubMed
22028494Phase I Study of Topotecan, Ifosfamide, and Etoposide (TIME) with autologous stem cell transplant in refractory cancer: pharmacokinetic and pharmacodynamic correlates.Clin Cancer Res2011https://conductscience.org/library/papers/22028494PubMed
12373594Platinum drugs in the treatment of non-small-cell lung cancer.Br J Cancer2002https://conductscience.org/library/papers/12373594PubMed
12182684High-dose chemotherapy and stem cell support for breast cancer: where are we now?Drugs Aging2002https://conductscience.org/library/papers/12182684PubMed
11710823Sequential detection of alphafetoprotein-bearing cells in blood stem cell fraction of germ cell tumour patients.Br J Cancer2001https://conductscience.org/library/papers/11710823PubMed
11161394A randomized trial of amifostine in patients with high-dose VIC chemotherapy plus autologous blood stem cell transplantation.Br J Cancer2001https://conductscience.org/library/papers/11161394PubMed
10745265Multi-purpose silastic dual-lumen central venous catheters for both collection and transplantation of hematopoietic progenitor cells.Bone Marrow Transplant2000https://conductscience.org/library/papers/10745265PubMed
9010989Fatigue in women treated with bone marrow transplantation for breast cancer: a comparison with women with no history of cancer.Support Care Cancer1997https://conductscience.org/library/papers/9010989PubMed
8847558Delayed, transient encephalopathy after marrow transplantation: case reports and MRI findings in four patients.J Neurooncol1996https://conductscience.org/library/papers/8847558PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/7844593

GET https://conductscience.org/api/papers/v1/7844593/authors